Published peptide research references
Abaloparatide
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.
Richard Eastell, Jacques P Brown, Robert A Adler, E Michael Lewiecki, Neil Binkley, Eric S Orwoll, David Kendler, Bruce H Mitlak, Yamei Wang · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis.
Laila Tabatabai, Felicia Cosman, Jeffrey R Curtis, Kristi T DeSapri, Clayton T LaBaume, Jean-Yves Reginster, René Rizzoli, Bernard Cortet, Yamei Wang, Joseph Chiodo, Bruce H Mitlak · Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025
PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
Charlotte Beaudart, Nicola Veronese, Jonathan Douxfils, Jotheeswaran Amuthavalli Thiyagarajan, Francesco Bolzetta, Paolo Albanese, Gianpaolo Voltan, Majed Alokail, Nicholas C Harvey, Nicholas R Fuggle, Olivier Bruyère, René Rizzoli · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
Probability of achieving bone mineral density treatment targets with abaloparatide and teriparatide.
Felicia Cosman, Bruce H Mitlak, Yamei Wang, Leny Pearman, Carolina A Moreira, E Michael Lewiecki, Steven R Cummings · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis.
Neil P Sheth, James Russell Smith, Renaud Winzenrieth, Ludovic Humbert, Yamei Wang, John I Boxberger, Mathias P Bostrom · The Journal of bone and joint surgery. American volume · 2024
The Safety and Efficacy of Abaloparatide on Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis.
Fuxin Xu, Yurun Wang, Xinjian Zhu · Clinical therapeutics · 2024
Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
Toshio Matsumoto, Teruki Sone, Akiko Yamashita, Tetsuo Inoue · Journal of bone and mineral metabolism · 2023
Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Chelsea Ayers, Devan Kansagara, Brittany Lazur, Rongwei Fu, Amy Kwon, Curtis Harrod · Annals of internal medicine · 2023
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
E Michael Lewiecki, Edward Czerwinski, Chris Recknor, Anna Strzelecka, Guillermo Valenzuela, Mary Lawrence, Stuart Silverman, Jose Cardona, Susan M Nattrass, Neil Binkley, Miriam Annett, Leny Pearman · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023
Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: A systematic review and Bayesian network meta-analysis.
Alexander H Seeto, Mina Tadrous, Abadi K Gebre, Joshua R Lewis, Howard A Fink, Peter R Ebeling, Alexander J Rodríguez · Bone · 2023
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.
Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid · BMJ (Clinical research ed.) · 2023
The effects of abaloparatide on hip geometry and biomechanical properties in Japanese osteoporotic patients assessed using DXA-based hip structural analysis: results of the Japanese phase 3 ACTIVE-J trial.
Teruki Sone, Kazuhiro Ohnaru, Takumi Sugai, Akiko Yamashita, Nobukazu Okimoto, Tetsuo Inoue, Toshio Matsumoto · Archives of osteoporosis · 2023
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial.
Edward Czerwinski, Jose Cardona, Rafal Plebanski, Chris Recknor, Tamara Vokes, Kenneth G Saag, Neil Binkley, E Michael Lewiecki, Jonathan Adachi, Dorota Knychas, David Kendler, Eric Orwoll · Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
Abaloparatide: A review of preclinical and clinical studies.
Mikkel Bo Brent · European journal of pharmacology · 2021
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Benjamin Z Leder, Bruce Mitlak, Ming-Yi Hu, Gary Hattersley, Richard S Bockman · The Journal of clinical endocrinology and metabolism · 2020
Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
Sharmistha Bhattacharyya, Subhashis Pal, Naibedya Chattopadhyay · Biochemical pharmacology · 2019
Abaloparatide: A new pharmacological option for osteoporosis.
Allyson Sleeman, Jennifer N Clements · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2019
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis.
Patricia Barrionuevo, Ekta Kapoor, Noor Asi, Fares Alahdab, Khaled Mohammed, Khalid Benkhadra, Jehad Almasri, Wigdan Farah, Maria Sarigianni, Kalpana Muthusamy, Alaa Al Nofal, Qusay Haydour · The Journal of clinical endocrinology and metabolism · 2019
Precisely Controlled Delivery of Abaloparatide through Injectable Hydrogel to Promote Bone Regeneration.
Ziyu Ning, Baoyu Tan, Bo Chen, Dzi Shing Aaron Lau, Tak Man Wong, Tianhao Sun, Songlin Peng, Zhaoyang Li, William Weijia Lu · Macromolecular bioscience · 2019
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Henry G Bone, Felicia Cosman, Paul D Miller, Gregory C Williams, Gary Hattersley, Ming-Yi Hu, Lorraine A Fitzpatrick, Bruce Mitlak, Socrates Papapoulos, René Rizzoli, Robin K Dore, John P Bilezikian · The Journal of clinical endocrinology and metabolism · 2018
Abaloparatide: Review of a Next-Generation Parathyroid Hormone Agonist.
Eric G Boyce, Yvonne Mai, Christopher Pham · The Annals of pharmacotherapy · 2018
Abaloparatide: First Global Approval.
Matt Shirley · Drugs · 2017
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.
Carolina A Moreira, Lorraine A Fitzpatrick, Yamei Wang, Robert R Recker · Bone · 2017
Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis.
Sri Harsha Tella, Anuhya Kommalapati, Ricardo Correa · Cureus · 2017
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Paul D Miller, Gary Hattersley, Bente Juel Riis, Gregory C Williams, Edith Lau, Luis Augusto Russo, Peter Alexandersen, Cristiano A F Zerbini, Ming-yi Hu, Alan G Harris, Lorraine A Fitzpatrick, Felicia Cosman · JAMA · 2016